Literature DB >> 26791602

The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.

Jenny L Wilkerson1, Micah J Niphakis2, Travis W Grim2, Mohammed A Mustafa2, Rehab A Abdullah2, Justin L Poklis2, William L Dewey2, Hamid Akbarali2, Matthew L Banks2, Laura E Wise2, Benjamin F Cravatt2, Aron H Lichtman2.   

Abstract

Serious clinical liabilities associated with the prescription of opiates for pain control include constipation, respiratory depression, pruritus, tolerance, abuse, and addiction. A recognized strategy to circumvent these side effects is to combine opioids with other antinociceptive agents. The combination of opiates with the primary active constituent of cannabis (Δ(9)-tetrahydrocannabinol) produces enhanced antinociceptive actions, suggesting that cannabinoid receptor agonists can be opioid sparing. Here, we tested whether elevating the endogenous cannabinoid 2-arachidonoylglycerol through the inhibition of its primary hydrolytic enzyme monoacylglycerol lipase (MAGL), will produce opioid-sparing effects in the mouse chronic constriction injury (CCI) of the sciatic nerve model of neuropathic pain. The dose-response relationships of i.p. administration of morphine and the selective MAGL inhibitor 2,5-dioxopyrrolidin-1-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate (MJN110) were tested alone and in combination at equieffective doses for reversal of CCI-induced mechanical allodynia and thermal hyperalgesia. The respective ED50 doses (95% confidence interval) of morphine and MJN110 were 2.4 (1.9-3.0) mg/kg and 0.43 (0.23-0.79) mg/kg. Isobolographic analysis of these drugs in combination revealed synergistic antiallodynic effects. Acute antinociceptive effects of the combination of morphine and MJN110 required μ-opioid, CB1, and CB2 receptors. This combination did not reduce gastric motility or produce subjective cannabimimetic effects in the drug discrimination assay. Importantly, combinations of MJN110 and morphine given repeatedly (i.e., twice a day for 6 days) continued to produce antiallodynic effects with no evidence of tolerance. Taken together, these findings suggest that MAGL inhibition produces opiate-sparing events with diminished tolerance, constipation, and cannabimimetic side effects.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26791602      PMCID: PMC4809319          DOI: 10.1124/jpet.115.229971

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  87 in total

1.  Intrathecal HIV-1 envelope glycoprotein gp120 induces enhanced pain states mediated by spinal cord proinflammatory cytokines.

Authors:  E D Milligan; K A O'Connor; K T Nguyen; C B Armstrong; C Twining; R P Gaykema; A Holguin; D Martin; S F Maier; L R Watkins
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

2.  Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord.

Authors:  U Arvidsson; M Riedl; S Chakrabarti; J H Lee; A H Nakano; R J Dado; H H Loh; P Y Law; M W Wessendorf; R Elde
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

3.  Novel 3-substituted rimonabant analogues lack Δ(9) -tetrahydrocannabinol-like abuse-related behavioural effects in mice.

Authors:  Dm Walentiny; Re Vann; A Mahadevan; R Kottani; R Gujjar; Jl Wiley
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

4.  Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord.

Authors:  A G Hohmann; E M Briley; M Herkenham
Journal:  Brain Res       Date:  1999-03-20       Impact factor: 3.252

5.  Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.

Authors:  Steven G Kinsey; Laura E Wise; Divya Ramesh; Rehab Abdullah; Dana E Selley; Benjamin F Cravatt; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2013-02-14       Impact factor: 4.030

6.  Cannabinoid-opioid interaction in chronic pain.

Authors:  D I Abrams; P Couey; S B Shade; M E Kelly; N L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2011-11-02       Impact factor: 6.875

7.  Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.

Authors:  A R Schatz; M Lee; R B Condie; J T Pulaski; N E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  1997-02       Impact factor: 4.219

8.  Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia.

Authors:  J Desroches; J-F Bouchard; L Gendron; P Beaulieu
Journal:  Neuroscience       Date:  2013-12-21       Impact factor: 3.590

9.  Brain monoglyceride lipase participating in endocannabinoid inactivation.

Authors:  T P Dinh; D Carpenter; F M Leslie; T F Freund; I Katona; S L Sensi; S Kathuria; D Piomelli
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

10.  Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.

Authors:  S G Kinsey; J Z Long; S T O'Neal; R A Abdullah; J L Poklis; D L Boger; B F Cravatt; A H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2009-06-05       Impact factor: 4.030

View more
  21 in total

1.  Effects of centrally administered endocannabinoids and opioids on orofacial pain perception in rats.

Authors:  Marek Zubrzycki; Anna Janecka; Andreas Liebold; Mechthild Ziegler; Maria Zubrzycka
Journal:  Br J Pharmacol       Date:  2017-08-30       Impact factor: 8.739

2.  The Effects of Morphine, Baclofen, and Buspirone Alone and in Combination on Schedule-Controlled Responding and Hot Plate Antinociception in Rats.

Authors:  Jenny L Wilkerson; Jasmine S Felix; Luis F Restrepo; Mohd Imran Ansari; Andrew Coop; Lance R McMahon
Journal:  J Pharmacol Exp Ther       Date:  2019-06-24       Impact factor: 4.030

Review 3.  The cannabinoid system and pain.

Authors:  Stephen G Woodhams; Victoria Chapman; David P Finn; Andrea G Hohmann; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2017-06-15       Impact factor: 5.250

4.  The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.

Authors:  Jenny L Wilkerson; Sudeshna Ghosh; Mohammed Mustafa; Rehab A Abdullah; Micah J Niphakis; Roberto Cabrera; Rafael L Maldonado; Benjamin F Cravatt; Aron H Lichtman
Journal:  Neuropharmacology       Date:  2016-11-25       Impact factor: 5.250

5.  The Endocannabinoid System Alleviates Pain in a Murine Model of Cancer-Induced Bone Pain.

Authors:  A L Thompson; S A Grenald; H A Ciccone; N BassiriRad; M J Niphakis; B F Cravatt; T M Largent-Milnes; T W Vanderah
Journal:  J Pharmacol Exp Ther       Date:  2020-02-13       Impact factor: 4.030

6.  Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.

Authors:  Richard A Slivicki; Shahin A Saberi; Vishakh Iyer; V Kiran Vemuri; Alexandros Makriyannis; Andrea G Hohmann
Journal:  J Pharmacol Exp Ther       Date:  2018-10-01       Impact factor: 4.030

7.  Monoacylglycerol Lipase Inhibitors Reverse Paclitaxel-Induced Nociceptive Behavior and Proinflammatory Markers in a Mouse Model of Chemotherapy-Induced Neuropathy.

Authors:  Zachary A Curry; Jenny L Wilkerson; Deniz Bagdas; S Lauren Kyte; Nipa Patel; Giulia Donvito; Mohammed A Mustafa; Justin L Poklis; Micah J Niphakis; Ku-Lung Hsu; Benjamin F Cravatt; David A Gewirtz; M Imad Damaj; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2018-03-14       Impact factor: 4.030

Review 8.  Endocannabinoid Signaling in the Central Amygdala and Bed Nucleus of the Stria Terminalis: Implications for the Pathophysiology and Treatment of Alcohol Use Disorder.

Authors:  Gaurav Bedse; Samuel W Centanni; Danny G Winder; Sachin Patel
Journal:  Alcohol Clin Exp Res       Date:  2019-08-21       Impact factor: 3.455

Review 9.  The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.

Authors:  Giulia Donvito; Sara R Nass; Jenny L Wilkerson; Zachary A Curry; Lesley D Schurman; Steven G Kinsey; Aron H Lichtman
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

10.  Median Nerve Stimulation as a Nonpharmacological Approach to Bypass Analgesic Tolerance to Morphine: A Proof-of-Concept Study in Mice.

Authors:  Ming Tatt Lee; Yi-Hung Chen; Ken Mackie; Lih-Chu Chiou
Journal:  J Pain       Date:  2020-10-15       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.